Talus Bio names Chris Joyce, MBA as VP of Business Development to drive pharma deals and advance TF therapeutics

Talus Bio hired Chris Joyce, MBA as VP of Business Development to accelerate pharma partnerships and advance its transcription factor therapeutics, including two programs targeting TBXT for non-small cell lung cancer and NONO-related androgen receptor splicing in castration-resistant prostate cancer.

AAlex Federation TTalus Bioscience